

Medical Directive

Title:	Allergy Injection	Assigned Number:	001	
Activation Date:	July 1, 2011	Review due by:	December 2025	
Approval Signature & Date				
Medical Director: Date Reviewed: Feb 23, 2024				
Clinical Services Director: <i>Lin Marghenful</i> Date Reviewed: Feb 23, 2024				
Order and/or Delegated Procedure:		Appendix Attac Title:	Appendix Attached: Yes No Title:	
Administration of Allergen Injections by Registered Nurses/Registered Practical Nurses.				
Recipient Patients:		Appendix Attac Title:	Appendix Attached: Yes No Title:	
All active patients of Thames Valley Family Health Team who require administration of allergen injections.				
Authorized Implementers:		Appendix Attac Title:	Appendix Attached: 🔲 Yes 🖂 No Title:	
Thames Valley Family Health Team Registered Nurses/Registered Practical Nurses (RN/RPN) * herein referred to as the implementer.				
* The implementer must receive orientation from the Educator with regards to the task. The implementer must have completed orientation and educational requirements of Emergency Treatment of Anaphylaxis/Severe Allergic Reactions to Allergy Injections or Immunizations medical directive and is encouraged to review Emergency Treatment of Anaphylaxis/Severe Allergic Reactions to Allergy Injections or Immunizations medical directive to ensure all required supplies and reference materials are available in the case of an emergency. The implementer must sign the Implementer Performance Readiness Form electronically via HR Downloads after successful completion of the orientation (and quiz, if applicable) indicating acceptance of this medical directive.				

Indications:		Appendix Attached	ppendix Attached: 🛛 Yes 🗌 No		
		Title: Appendix 1 – Information & Conse	Allergy Injection Patient		
1. Verbal consent received from the patient/substitute decision maker for the implementer to implement this medical directive.					
 Patient has been prescribed specific allergen solution by a physician/specialist. Patient has signed TVFHT allergy consent form for storage of allergen serum (see Appendix 1) The allergen vial is accompanied by a current order-to-follow describing dosage and interval. The patient must agree to remain onsite for 30 minutes following administration of the injection. In case of adverse reaction, emergency drugs and equipment must be available. 					
Contraindications:		Appendix Attached: 🔲 Yes 🖾 No Title:			
 No verbal consent from patient or substitute decision maker for the implementer to implement this medical directive. Individuals that have a temperature over 38° degrees Celsius or are feeling unwell. Individuals who developed a Grade 2 or more severe reaction (based on the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System) after the last injection. 					
Grade 1	Grade 2	Grade 3	Grade 4 Grade 5		
	Symptom(s)/sign(s) of more than 1 organ system present or Lower respiratory Asthma: cough, wheezing, shortness of breath (e.g. than 40% PEF or FEV1 drop, responding to an inhaler bronchodilator) or Gastrointestinal Abdominal cramps, vomiting, or diarrhea or Other Uterine cramps	d or Upper respiratory Laryngeal, uvula, or tongue edema with or without stridor	Cardiovascular Hypotension with or without loss of consciousness		
 patient's provider/allergist's instructions to determine appropriate dose of allergen injection. 5. Implementer has not received signed Implementer Performance Readiness Form for Medical Directive for Emergency Treatment of Anaphylaxis/Severe Allergic Reactions to Allergy Injections or Immunizations 					
Consent:			Appendix Attached: 🔲 Yes 🖾 No		
Title: 1. Patients of Thames Valley Family Health Team. 2. The implementer obtains verbal consent from patient/substitute decision maker prior to the implementation of care.					

Guidelines for Implementing the Order/ Procedure:	Appendix Attached: 🛛 Yes 🗌 No Title:		
Patients who meet the Indications described above:			
1. The allergen injection will be given subcutaneous to the upper arm according to the manufacturer's instructions and the written order included with the allergen vial.			
2. The patient is asked to remain in the clinic for 30 minutes post injection.			

- 3. If at any time the patient experiences any signs of a Grade 2 or more severe reaction (based on the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System) or anaphylaxis, activate Medical Directive for Emergency Treatment of Anaphylaxis/Severe Allergic Reactions to Allergy Injections or Immunizations
- 4. After 30 minutes and no signs of a Grade 2 or more severe reaction (based on the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System) or anaphylaxis, the patient is to be reassessed by the implementer before discharge. The injection site must be inspected.
 - If the local reaction displays redness, swelling or wheal greater than the size of the patient's palm, discuss reaction with authorizer or patient's physician/allergist, discharge as per order of authorizer or patient's physician/allergist. (Dose adjustments in the injection is not necessary when the local reaction is smaller than the size of the patient's palm, but it is unclear whether dose adjustments is necessary beyond this size and the situation should be notified to the authorizer and to consider a reassessment by the prescribing allergist)

Discharge instructions:

- 1. Patients are to be reminded
 - a. To seek emergency medical care should a Grade 2 or more severe reaction (based on the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System) or anaphylaxis develop.
 - b. To notify the provider of any reaction at the next visit.
- 2. All information pertaining to the injections is documented on the **Order Sheet** maintained with the allergen vial and/or in the patient record according to standard documentation practices. *
- * Potter, P.A. & Perry, A.G. (2006). Fundamentals of Nursing. St. Louis: Mosby. College of Nurses of Ontario (2008). CNO Practice Standard: Documentation

Safety of Allergen Immunotherapy: A Review of Premedication and Dose Adjustment. Immunotherapy. 2012;4(3):315-322. https://www.medscape.com/viewarticle/762698_1. Accessed Aug 27, 2023

Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017 Feb; 17(1): 55–59. <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644500/#:~:text=Adverse%20allergic%20reactions%20to%20SCIT,reactions%20%5B7%E2</u> <u>%80%9310%5D</u>. Accessed Aug 27, 2023


Injection Immunotherapy for Inhalant Allergens. Middleton's Allergy: Principles and Practice, 85, 1401-1419.e1. Accessed via ClinicalKey on Aug 27, 2023

Immunotherapy Manual Canadian Society of Allergy & Clinical Immunology 2016. <u>http://csaci.ca/wp-content/uploads/2017/12/IT-Manual-2016-5-July-2017-rev.pdf</u>. Accessed Aug 27, 2023

Documentation and Communication:		Appendix Attached: 🗌 Yes 🖂 No	
		Title:	
	 Documentation in the patient's medical record needs to include the name and number of the directive, name of the implementer (including credential), and name of the authorizer responsible for the directive and patient. Specific sites of immunization must also be noted along with the Lot Number and Expiration Date. Information regarding implementation of the procedure and the patient's response should be documented in accordance with standard documentation practice. * 		
*	Potter, P.A. & Perry, A.G. (2006). Fundamentals of Nursing. St. Louis: Mosby. College of Nurses of Ontario (2008). CNO Practice Standard: Documentation		
Review and Quality Monitoring Guidelines:		Appendix Attached: 🔲 Yes 🖂 No	
		Title:	
1.	. The Directive remains in force until and unless amendment occurs. Review will occur biennially. In case the Medical Director identifies the need to change the Medical Directive, at least one TVFHT member of the implementing disciplines will be consulted.		
2.	At any such time that issues related to the use of this directive are identified, the team must act upon the concerns immediately by identifying these concerns to the Medical Director. The Medical		
3.	Director will review these concerns and consult with at least one TVFHT member of the implementing disciplines, before necessary changes are made. If new information becomes available between routine renewals, and particularly if this new information has implications for unexpected outcomes, the directive will be reviewed by the Medical Director and a minimum of one TVFHT member of the implementing disciplines.		
Approving Authorizer(s):		Appendix Attached: 🗌 Yes 🖂 No	
•		Title:	
Authorizer Approval Form signed in HR Downloads by Medical Director.			



Appendix 1: Allergy Injection Patient Information & Consent



 If you think you might be pregnant, tell your doctor or nurse. Immunotherapy is generally felt to be safe during pregnancy; however, the dosage should not be increased and your doctor may wish to reduce the dose while you are pregnant.

Page 1 of 2

- You should not receive an allergy injection if you:
 - Have a fever or extended illness for any reason.
 - Are wheezing, short of breath or having an exacerbation of asthma symptoms.
 - Are taking a Beta-Blocker. These are drugs used to treat irregular heartbeats, headaches, eve problems and high blood pressure.
 - Allergy extracts should be refrigerated between injections, but never frozen.

These recommendations are based on best practice guidelines (courtesy of the Allergy and Immunology Program of St. Joseph's Health Care London).

Patient acknowledgement:

I have read and understood the above Allergy Injection Information and agree to the Thames Valley Family Health Team's policy of waiting 30 minutes after injection for systemic reaction monitoring.

Patient or guardian signature

Date

Witness signature

Storage of patient injectable/medication in our refrigerator or clinic:

We provide you with the service of storing (labelled) patient vials (injectables, allergy serum, vaccines, etc.) between prescribed injection visits.

We are not liable for the compromise in the integrity of the medication due to handling before receiving the medication or for loss or compromise of integrity due to power outage, storage equipment failure or catastrophic event.

We are not liable for any loss or theft during storage.

This is a voluntary service and it is your option to keep your vial with you personally and bring with you to each visit.

Patient or guardian signature

Date

Witness signature

**Once signed this consent should be scanned into patient's record.

Page 2 of 2